U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07899346) titled 'Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome' on Oct. 20.
Brief Summary: This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your body handles them), pharmacokinetics (PK) (how a drug is taken into your body, spread throughout, broken down, and eliminated), clinical activity (does the drug make patients feel better), immunogenicity (how the immune system responds to the drug), and serum virus neutralizing antibody response...